--- title: "投资者警示：Robbins LLP 通知投资者关于 Corcept Therapeutics Inc. 的集体诉讼" description: "Robbins LLP 宣布对在 2024 年 10 月 31 日至 2025 年 12 月 30 日期间购买 Corcept Therapeutics Inc.（纳斯达克：CORT）股票的投资者提起集体诉讼。诉讼指控 Corcept 在其产品候选药物 relacorilant 治疗高皮质醇血症的可行性方面误导了投资者。美国食品药品监督管理局（FDA）对支持 Corcept 新药申请的临床证据表示" type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/276498684.md" published_at: "2026-02-21T01:24:48.000Z" --- # 投资者警示：Robbins LLP 通知投资者关于 Corcept Therapeutics Inc. 的集体诉讼 > Robbins LLP 宣布对在 2024 年 10 月 31 日至 2025 年 12 月 30 日期间购买 Corcept Therapeutics Inc.（纳斯达克：CORT）股票的投资者提起集体诉讼。诉讼指控 Corcept 在其产品候选药物 relacorilant 治疗高皮质醇血症的可行性方面误导了投资者。美国食品药品监督管理局（FDA）对支持 Corcept 新药申请的临床证据表示担忧，导致在 FDA 于 2025 年 12 月 31 日发出完整回应函后，股价大幅下跌。股东可能有资格参与该集体诉讼 **Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit** Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. **The Allegations:** Robbins LLP is Investigating Allegations that Corcept Therapeutics Incorporated (CORT) Misled Investors Regarding the Viability of its New Product Candidate According to the complaint, one of Corcept's lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”). During the class period, defendants represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were “powerful support” for the New Drug Application (“NDA”) that Corcept submitted to the U.S. Food and Drug Administration (“FDA”) for this indication. Defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the class period, Defendants repeatedly told investors that “relacorilant is approaching approval.” Plaintiff alleges that in truth, the FDA had raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result there was a known material risk that Corcept's relacorilant NDA would not be approved. The complaint continues that on December 31, 2025, Corcept revealed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” As a result of this disclosure, the price of Corcept common stock declined from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025, or 50.4%. **What Now**: You may be eligible to participate in the class action against Corcept Therapeutics Incorporated. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. ***All representation is on a contingency fee basis. Shareholders pay no fees or expenses.*** **About Robbins LLP****:** A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Corcept Therapeutics Incorporated settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260220335365/en/ ### Related Stocks - [BBH.US - 生物科技 ETF - VanEck Vectors](https://longbridge.com/zh-CN/quote/BBH.US.md) - [IBB.US - 纳斯达克生物科技指数 ETF - iShares Nasdaq](https://longbridge.com/zh-CN/quote/IBB.US.md) - [XLV.US - 医疗业 ETF - SPDR](https://longbridge.com/zh-CN/quote/XLV.US.md) - [IHE.US - 美国制药 ETF - iShares](https://longbridge.com/zh-CN/quote/IHE.US.md) - [PBE.US - 动态生物技术与基因组 ETF - Invesco](https://longbridge.com/zh-CN/quote/PBE.US.md) - [FBT.US - 纽交所高增长板生物技术指数 ETF - First Trust](https://longbridge.com/zh-CN/quote/FBT.US.md) - [VHT.US - 医疗业 ETF - Vanguard](https://longbridge.com/zh-CN/quote/VHT.US.md) - [ARKG.US - 基因改革 ETF - ARK](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [SBIO.US - 医药突破 ETF - ALPS](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [CORT.US - Corcept医疗](https://longbridge.com/zh-CN/quote/CORT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 阿伯丁集團有限公司持有 Crinetics Pharmaceuticals, Inc. $CRNX 價值 1416 萬美元的股票 | 阿伯丁集團 plc 在第三季度將其在 Crinetics Pharmaceuticals, Inc. 的股份增加了 21.3%，目前持有 339,949 股，價值 1416 萬美元。其他機構投資者也調整了他們的持股。分析師對 CRNX 的評 | [Link](https://longbridge.com/zh-CN/news/276426109.md) | | BUZZ-Traws Pharma 在 FDA 將流感藥物申請置於臨牀擱置後股價下跌 | Traws Pharma 的股票在盤前交易中下跌了 20.81%，至 1.58 美元，此前美國 FDA 因對 tivoxavir marboxil 的突變性數據表示擔憂，將其新藥申請置於臨牀暫停狀態。該公司表示，此次暫停不會影響美國以外的正 | [Link](https://longbridge.com/zh-CN/news/276337113.md) | | Madrigal 製藥因 Rezdiffra 的銷售，第四季度收入大幅增長 | Madrigal 製藥報告第四季度收入為 3.211 億美元，較去年大幅增長，儘管出現了淨虧損。該公司預計，由於疾病意識的提高，Rezdiffra 的銷售將實現強勁增長，並計劃與 FDA 就第二階段試驗設計進行諮詢。MASH 管道已通過新項 | [Link](https://longbridge.com/zh-CN/news/276330392.md) | | 津巴布韋推出新型 HIV 預防藥物 lenacapavir | 津巴布韋推出了長效 HIV 預防藥物 lenacapavir，目標是覆蓋超過 46,000 名高風險個體，分佈在 24 個地點。該項目由美國和全球基金資助，分階段進行，衞生部長道格拉斯·蒙貝肖拉強調了其在抗擊 HIV 中的重要性。lenac | [Link](https://longbridge.com/zh-CN/news/276333424.md) | | 關鍵事實：Candel Therapeutics 獲得 1 億美元資金；計劃推出新藥 | Candel Therapeutics 已與 RTW Investments 達成了一項 1 億美元的融資協議，用於其治療藥物 Aglatimagene Besadenovec，待 FDA 批准，且根據美國銷售情況支付版税。Candel T | [Link](https://longbridge.com/zh-CN/news/276481541.md) | --- > **免责声明**：本文内容仅供参考，不构成任何投资建议。